SEC Form 10-Q filed by Sleep Number Corporation

5/12/26 7:06:27 AM ET

$SNBR

Home Furnishings

Consumer Discretionary

Get the next $SNBR alert in real time by email

snbr-20260404

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 4, 2026


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 000-25121

_______________________________________________________________________

SLEEP NUMBER CORPORATION

(Exact name of registrant as specified in its charter)


Minnesota		41-1597886
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)


1001 Third Avenue South
Minneapolis,	Minnesota	55404
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (763) 551-7000

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	SNBR	Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities

Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),

and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant

to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant

was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting

company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting

company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☒
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of April 4, 2026, 23,049,000 shares of the registrant’s Common Stock were outstanding.


i \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

INDEX


		Page
PART I: FINANCIAL INFORMATION		1

Item 1.	Financial Statements (unaudited)	1
	Condensed Consolidated Balance Sheets	1
	Condensed Consolidated Statements of Operations	2
	Condensed Consolidated Statements of Shareholders' Deficit	3
	Condensed Consolidated Statements of Cash Flows	4
	Notes to Condensed Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	27
Item 4.	Controls and Procedures	27

PART II: OTHER INFORMATION		28

Item 1.	Legal Proceedings	28
Item 1A.	Risk Factors	28
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28
Item 3.	Defaults Upon Senior Securities	28
Item 4.	Mine Safety Disclosures	28
Item 5.	Other Information	28
Item 6.	Exhibits	29
SIGNATURES		30


1 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of contents

PART I: FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(in thousands, except per share amounts)


	April 4, 2026	January 3, 2026
Assets	(unaudited)	(audited)
Current assets:
Cash and cash equivalents	$1,484	$1,693
Accounts receivable, net of allowances of $656 and $694, respectively	13,354	15,502
Inventories	78,216	82,233
Prepaid expenses	19,727	13,656
Other current assets	30,694	36,873
Total current assets	143,475	149,957

Non-current assets:
Property and equipment, net	73,755	86,528
Operating lease right-of-use assets	295,315	311,723
Goodwill and intangible assets, net	66,131	66,186
Deferred income taxes	399	399
Other non-current assets	61,933	65,267
Total assets	$641,008	$680,060

Liabilities and Shareholders’ Deficit
Current liabilities:
Borrowings under credit facility	$605,600	$588,200
Accounts payable	116,395	117,977
Customer prepayments	43,338	39,527
Accrued sales returns	12,266	12,817
Compensation and benefits	19,415	14,975
Taxes and withholding	10,908	11,429
Operating lease liabilities	79,340	81,191
Other current liabilities	44,447	46,430
Total current liabilities	931,709	912,546

Non-current liabilities:
Operating lease liabilities	268,697	273,111
Other non-current liabilities	66,921	72,878
Total liabilities	1,267,327	1,258,535

Shareholders’ deficit:
Undesignated preferred stock; 5,000 shares authorized, no shares issued and outstanding	—	—
Common stock, $0.01 par value; 142,500 shares authorized, 23,049 and 22,860 shares issued and outstanding, respectively	230	229
Additional paid-in capital	34,906	32,454
Accumulated deficit	(661,455)	(611,158)
Total shareholders’ deficit	(626,319)	(578,475)
Total liabilities and shareholders’ deficit	$641,008	$680,060

See accompanying notes to condensed consolidated financial statements.


2 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(unaudited - in thousands, except per share amounts)


	Three Months Ended
	April 4, 2026	March 29, 2025
Net sales	$318,987	$393,261
Cost of sales	134,372	152,726
Gross profit	184,615	240,535

Operating expenses:
Sales and marketing	160,795	189,103
General and administrative	33,592	38,619
Research and development	5,348	10,903
Restructuring costs	21,736	60
Total operating expenses	221,471	238,685
Operating (loss) income	(36,856)	1,850
Interest expense, net	13,103	11,081
Loss before income taxes	(49,959)	(9,231)
Income tax expense (benefit)	338	(585)
Net loss	$(50,297)	$(8,646)

Basic and diluted net loss per share:
Net loss per share – basic and diluted	$(2.19)	$(0.38)
Weighted-average shares – basic and diluted	22,991	22,706

See accompanying notes to condensed consolidated financial statements.


3 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Condensed Consolidated Statements of Shareholders’ Deficit

(unaudited - in thousands)


	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total
	Shares	Amount	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at January 3, 2026	22,860	$229	$32,454	$(611,158)	$(578,475)
Net loss	—	—	—	(50,297)	(50,297)
Stock-based compensation	292	2	2,824	—	2,826
Repurchases of common stock	(103)	(1)	(372)	—	(373)
Balance at April 4, 2026	23,049	$230	$34,906	$(661,455)	$(626,319)


	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total
	Shares	Amount	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at December 28, 2024	22,388	224	27,390	(479,200)	(451,586)
Net loss	—	—	—	(8,646)	(8,646)
Stock-based compensation	346	3	3,948	—	3,951
Repurchases of common stock	(74)	—	(563)	—	(563)
Balance at March 29, 2025	22,660	227	30,775	(487,846)	(456,844)

See accompanying notes to condensed consolidated financial statements.


4 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(unaudited - in thousands)


	Three Months Ended
	April 4, 2026	March 29, 2025
Cash flows from operating activities:
Net loss	$(50,297)	$(8,646)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	12,371	14,836
Stock-based compensation	2,826	3,951
Inventory obsolescence write off	2,099	—
Loss on disposal and impairment of leased assets	17,539	17
Deferred income taxes	—	(1,321)
Changes in operating assets and liabilities:
Accounts receivable	2,148	3,291
Inventories	1,918	(724)
Income taxes	482	736
Prepaid expenses and other assets	(4,266)	781
Accounts payable	3,818	8,784
Customer prepayments	3,811	(6,576)
Accrued compensation and benefits	4,354	(9,686)
Other taxes and withholding	(1,003)	(1,925)
Other accruals and liabilities	(3,551)	(6,144)
Net cash used in operating activities	(7,751)	(2,626)

Cash flows from investing activities:
Purchases of property and equipment	(5,441)	(4,599)
Net cash used in investing activities	(5,441)	(4,599)

Cash flows from financing activities:
Net increase in short-term borrowings	13,805	9,087
Repurchases of common stock	(373)	(563)
Debt issuance costs	(449)	(1,558)
Net cash provided by financing activities	12,983	6,966

Net decrease in cash and cash equivalents	(209)	(259)
Cash and cash equivalents, at beginning of period	1,693	1,950
Cash and cash equivalents, at end of period	$1,484	$1,691

See accompanying notes to condensed consolidated financial statements.


5 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

1. Business and Summary of Significant Accounting Policies

Business & Basis of Presentation

The Company prepared the condensed consolidated financial statements as of and for the three months ended April 4,

2026 of Sleep Number Corporation and its 100%-owned subsidiaries (Sleep Number or the Company), without audit,

pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) and they reflect, in the opinion of

management, all normal recurring adjustments, including the elimination of all intra-entity balances and transactions,

necessary to present fairly its financial position as of April 4, 2026 and January 3, 2026, and the consolidated results of

operations and cash flows for the periods presented. The historical and quarterly consolidated results of operations may

not be indicative of the results that may be achieved for the full year or any future period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S.

Generally Accepted Accounting Principles (GAAP) have been condensed or omitted pursuant to such rules and

regulations. These condensed consolidated financial statements should be read in conjunction with the most recent

audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for

the fiscal year ended January 3, 2026 and other recent filings with the SEC.

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to

make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities,

disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the

reported amounts of sales, expenses and income taxes during the reporting period. Predicting future events is inherently

an imprecise activity and, as such, requires the use of judgment. As future events and their effects cannot be determined

with precision, actual results could differ significantly from these estimates. Changes in these estimates will be reflected in

the consolidated financial statements in future periods and could be material.

The Company’s critical accounting policies consist of stock-based compensation, warranty liabilities, revenue recognition

and valuation allowance for deferred tax assets.

Accounting Pronouncements Recently Adopted

In July 2025, the FASB issued ASU 2025-05, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit

Losses for Accounts Receivable and Contract Assets”, which provides a practical expedient related to the estimation of

expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for

under Topic 606, including those assets acquired in a business combination. This guidance is effective for the Company

for its fiscal year and all interim periods beginning January 4, 2026 on a prospective basis. The Company has elected the

practical expedient under the standard which permits an entity to assume that current conditions as of the balance sheet

date do not change for the remaining life of the current accounts receivable and current contract assets. This simplifies the

estimation process for short-term financial assets. The adoption of ASU 2025‑05 did not have a material impact on the

Company’s results of operations, cash flows or financial condition.

Going Concern

The Company’s financial statements have been prepared under the assumption that the Company will continue as a going

concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business for the

foreseeable future.

Historically, the Company has relied principally on liquidity generated from operating activities to fund the Company’s day-

to-day operations and service its debt. The Company has a history of net losses and negative operating cash flows and

expects to continue to incur additional losses in the future. Although the Company continues to pursue its turnaround

strategy “Sleep Number Shifts,” centered on product, marketing and distribution, as well as ongoing cost savings and

operating efficiencies, to reignite growth and increase financial resilience, the timing and realization of its turnaround

strategy cannot be guaranteed to ensure sufficient cash flow is generated to provide liquidity to meet the Company’s

obligations. While the Company was able to amend its Credit Agreement to provide that the lenders will forbear from


6 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

exercising certain rights and remedies in respect to certain events of default under the Credit Agreement (the “Specified

Defaults”) through the first week ending after July 1, 2026, and add a $25 million term loan facility with a maturity date of

June 30, 2026, the Company was not able to amend covenants beyond July 1, 2026 and therefore the Company

anticipates that it will not remain in compliance with the financial covenants of its Credit Agreement for the next twelve

months. These conditions and events raise substantial doubt about the Company’s ability to continue as a going concern.

Management’s plan to address the substantial doubt about the Company’s ability to continue as a going concern, as

described above, includes the following ongoing actions:

•execute the Company’s turnaround strategy centered on product, marketing and distribution with ongoing cost

savings and operating efficiencies to reignite growth and increase financial resilience;

•following the recent amendment of the Credit Agreement, the Company continues to engage with lenders to fulfill

the Company’s obligations under the credit facility and other provisions as needed; and

•work with financial advisors to negotiate with the lenders and identify and secure additional capital options,

alternative financing arrangements, strategic alternatives, or other comprehensive solutions to address the

Company’s capital structure and leverage needs to return to growth and create long-term value.

There can be no assurance of the Company’s ability to realize these plans. As a result, the Company has concluded that

management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern for at

least one year from the date of issuance of these financial statements.

The consolidated financial statements do not include any adjustments relating to the recoverability and classification of

recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this

uncertainty.

2. Fair Value Measurements

At both April 4, 2026 and January 3, 2026, the Company had $17 million of debt and equity securities that fund the

deferred compensation plan and are classified in other non-current assets. The Company also had corresponding

deferred compensation plan liabilities of $17 million at both April 4, 2026 and January 3, 2026 which are included in other

non-current liabilities. The majority of the debt and equity securities are Level 1 as they trade with sufficient frequency and

volume to enable the Company to obtain pricing information on an ongoing basis. Unrealized gains/(losses) on the debt

and equity securities offset those associated with the corresponding deferred compensation plan liabilities.

During the three months ended April 4, 2026, the Company continued to initiate cost savings and operational efficiencies

to reduce operating expenses and accelerate gross margin initiatives. As a result the Company recorded $22 million of

restructuring costs during the quarter. Refer to Note 12, Restructuring Costs for additional information. In the $22 million,

we recorded $18 million of long-lived asset impairment charges primarily related to lease right-of-use assets and property

and equipment. The restructuring costs are included on the Company’s condensed consolidated statements of operations.

All non-recurring fair value remeasurements discussed above were based on significant unobservable inputs (Level 3).

The remaining carrying value of net long-lived assets subject to impairment approximates fair value and was immaterial as

of April 4, 2026.

3. Inventories

Inventories consisted of the following (in thousands):


	April 4, 2026	January 3, 2026
Raw materials	$6,244	$5,842
Work in progress	143	137
Finished goods	71,829	76,254
	$78,216	$82,233


7 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

4. Goodwill and Intangible Assets, Net

Goodwill and Indefinite-lived Intangible Assets

Goodwill was $64.0 million at both April 4, 2026 and January 3, 2026. Indefinite-lived trade name/trademarks totaled

$1.4 million at both April 4, 2026 and January 3, 2026.

Definite-lived Intangible Assets

Patents were $2.0 million at both April 4, 2026 and January 3, 2026. Accumulated amortization was $1.3 million at April 4,

2026 and $1.2 million at January 3, 2026. Amortization expense was $0.1 million for both the three months ended April 4,

2026 and March 29, 2025.

Annual amortization for patents for subsequent years is as follows (in thousands):


2026 (excluding the three months ended April 4, 2026 )		$166
2027		222
2028		156
2029		99
2030		45
Total future amortization for definite-lived intangible assets		$688

5. Credit Agreement

As of April 4, 2026, the Company’s credit facility had a total commitment amount of $653 million. The credit facility, as

amended, is for general corporate purposes and to meet seasonal working capital requirements. The Amended and

Restated Credit and Security Agreement, dated February 14, 2018, among the Company, U.S. Bank National Association

and the several banks and other financial institutions from time to time party thereto (as amended, the Credit Agreement)

provides the lenders with a collateral security interest in substantially all of the Company’s assets and those of its

subsidiaries and requires the Company to comply with, among other things, a maximum Net Leverage Ratio and a

minimum Interest Coverage Ratio. The carrying amount of the outstanding borrowings under the Credit Agreement

approximates fair value because interest rates approximate the current rates available to the Company. Under the terms

of the Credit Agreement, the Company pays a variable rate of interest and a commitment fee based on the amended

terms below.

On November 4, 2025, the Company amended the Credit Agreement. The amendment, among other things: (a) extended

the maturity date of the Credit Agreement to December 3, 2027; (b) reduced the revolving credit facility from $485 million

to $475 million, which decreases further to $465 million on July 31, 2026; (c) replaced the leverage-based pricing grids

used to determine the Applicable Margin and Applicable Commitment Fee Rate (each as defined in the Credit Agreement)

in favor of (I) with respect to Applicable Margin for Term SOFR Loans, 4.25% starting January 1, 2027 and continuing

thereafter, and (II) with respect to the Applicable Commitment Fee Rate, 0.75% starting January 1, 2027 and continuing

thereafter; (d) on each Regularly Scheduled Payment Date (as defined in the Credit Agreement) occurring on and after

March 31, 2027, increases the amortization of outstanding term loans an additional $1,250,000 (for an aggregate

scheduled principal payment of $3,750,000); (e) terminated the accordion feature; (f) adjusted the permissible maximum

Net Leverage Ratio (as defined in the Credit Agreement) to (I) 4.75 to 1.00 for the quarterly reporting period ending April 4,

2026, (II) 4.80 to 1.00 for the quarterly reporting period ending July 4, 2026, and (III) 4.00 to 1.00 for each quarterly

reporting period thereafter; (g) adjusts the Liquidity financial covenant so that the Company must ensure that liquidity is no

lower than and $40 million for each monthly reporting period; (h) adjusts the permissible minimum Interest Coverage Ratio

to (I) 2.10 to 1.00 for the quarterly reporting periods ending January 3, 2026 and April 4, 2026, (II) 1.80 to 1.00 for the

quarterly reporting period ending July 4, 2026, (III) 2.10 to 1.00 for the reporting period ending October 3, 2026, and (IV)

2.20 to 1.00 for each quarterly reporting period occurring thereafter; (i) adds a new quarterly minimum EBITDA covenant

test that begins for the quarterly reporting period ending April 4, 2026; (j) adjusts the consolidated EBITDA calculation to

include an addback for certain expenses and costs incurred for the trailing twelve months for discontinued operations,

downsized functions and employment expenses for laid-off employees; and (k) provides for additional and more frequent


8 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

reporting requirements. In connection with the amendment, the Company also agreed to pay the lenders certain

amendment fees and to reimburse the lenders for certain expenses.

On April 27, 2026, the Company entered into a Forbearance Agreement and Thirteenth Amendment (the “Thirteenth

Amendment”) amending the Credit Agreement. The amendment, among other things: (a) adds a $25 million term loan

facility (the “2026 Term Loan”) that accrues interest at a rate per annum equal to the one-month term SOFR rate plus

8.00% and that matures on June 30, 2026, with a $5 million amortization payment due on June 1, 2026; (b) provides that

the lenders will forbear from exercising certain rights and remedies in respect of certain events of default under the Credit

Agreement (the “Specified Defaults”), subject to certain forbearance termination events; (c) requires that cash interest

payments in respect of all loans outstanding under the Credit Agreement be payable at least monthly; (d) permits the sale

of the Company’s claim for certain tariff refunds; (e) requires mandatory prepayments of the loans outstanding under the

Credit Agreement with any proceeds received from certain asset sales, equity issuances, debt incurrences, insurance

claims or condemnation or similar payments; (f) provides for additional and more frequent reporting requirements; (g)

adjusts the minimum liquidity financial covenant such that it does not apply from April 27, 2026 until the last Business Day

of the first week ending after July 1, 2026; (h) requires that the Company not permit disbursements or new draws under

the revolving credit facility outstanding under the Credit Agreement (the “Revolving Facility”) to exceed an agreed

permitted variance amount; and (i) requires the Company to satisfy certain milestones, including milestones relating to the

Company’s efforts to consummate a strategic transaction that is designed to maximize enterprise value and provide for

payment in full of the obligations under the Credit Agreement. Following such amendment, the Company was in

compliance with all covenants (other than with respect to the Specified Defaults).

The following table summarizes the Company’s borrowings under the credit facility ($ in thousands):


	April 4, 2026	January 3, 2026
Outstanding borrowings	$605,600	$588,200
Outstanding letters of credit	$8,300	$8,800
Additional borrowing capacity	$38,600	$58,000
Weighted-average interest rate	7.8%	7.8%

6. Leases

The Company leases its retail, office and manufacturing space under operating leases which, in addition to the minimum

lease payments, may require payment of a proportionate share of the real estate taxes and certain building operating

expenses. While the Company’s local market development approach generally results in long-term participation in given

markets, the retail store leases generally provide for an initial lease term of five to ten years. The Company’s office and

manufacturing leases provide for an initial lease term of up to fifteen years. In addition, the Company’s mall-based retail

store leases may require payment of variable rent based on net sales in excess of certain thresholds. Certain leases may

contain options to extend the term of the original lease. The exercise of lease renewal options is at the Company’s sole

discretion. Lease options are included in the lease term only if exercise is reasonably certain at lease commencement.

The Company’s lease agreements do not contain any material residual value guarantees. The Company also leases

vehicles and certain equipment under operating leases with an initial lease term of three to six years.

The Company’s operating lease costs include facility, vehicle and equipment lease costs, but exclude variable lease costs.

Operating lease costs are recognized on a straight-line basis over the lease term, after consideration of rent escalations

and rent holidays. The lease term for purposes of the calculation begins on the earlier of the lease commencement date or

the date the Company takes possession of the property. During lease renewal negotiations that extend beyond the original

lease term, the Company estimates straight-line rent expense based on current market conditions. Variable lease costs

are recorded when it is probable the cost has been incurred and the amount can be reasonably estimated. Future

payments for real estate taxes and certain building operating expenses for which the Company is obligated are not

included in operating lease costs.

At April 4, 2026, the Company’s finance right-of-use (ROU) assets and lease liabilities were not significant.


9 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

The Company evaluates its operating lease ROU assets for impairment whenever events or changes in circumstances

indicate that the carrying amount of the assets may not be recoverable. During the three months ended April 4, 2026,

certain office and retail locations have ceased operations or plan to cease operations in the near term but remain under

lease obligations. As a result, the Company recorded impairment charges of $18 million, which are included in

restructuring costs in the condensed consolidated statements of operations and cash flows. The Company continues to

monitor its real estate footprint and may incur additional impairment charges in future periods.

Lease costs were as follows (in thousands):


	Three Months Ended
	April 4, 2026	March 29, 2025
Operating lease costs(1)	$24,806	$26,537
Variable lease costs(2)	$(23)	$103

(1)Includes short-term lease costs which are not significant.

(2)Variable lease costs include adjustments to percentage rent.

The maturities of operating lease liabilities for subsequent years are as follows(1) (in thousands):


2026 (excluding the three months ended April 4, 2026)	$76,273
2027	90,860
2028	78,412
2029	57,745
2030	43,507
2031	31,089
Thereafter	30,179
Total operating lease payments(2)	408,065
Less: Interest	60,028
Present value of operating lease liabilities	$348,037

(1)Total operating lease payments exclude $2 million of legally binding minimum lease payments for leases signed but not yet commenced.

(2)Includes the current portion of $79 million for operating lease liabilities.

Other information related to operating leases was as follows:


	April 4, 2026	January 3, 2026
Weighted-average remaining lease term (in years)	4.9	5.0
Weighted-average discount rate	6.7%	6.7%


	Three Months Ended
(in thousands)	April 4, 2026	March 29, 2025
Cash paid for amounts included in present value of operating lease liabilities(1)	$25,840	$26,589
Right-of-use assets obtained in exchange for operating lease liabilities	$14,323	$7,711

(1)Cash paid for amounts included in present value of operating lease liabilities are included within the change in other accruals and liabilities within the

condensed consolidated statement of cash flows offset by non-cash right-of-use asset amortization and lease liability accretion.

7. Repurchases of Common Stock

For the three months ended April 4, 2026 and March 29, 2025, we repurchased $0.4 million and $0.6 million of common

stock in connection with the vesting of restricted stock grants. We made no purchases under the Board-approved stock

purchase plan in either period. As of April 4, 2026, the remaining authorization under the Board-approved $600 million

share repurchase program was $348 million.


10 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

8. Revenue Recognition

Deferred contract assets and deferred contract liabilities are included in the condensed consolidated balance sheets as

follows (in thousands):


	April 4, 2026	January 3, 2026
Deferred contract assets included in:
Other current assets	$25,969	$28,704
Other non-current assets	29,404	33,522
	$55,373	$62,226


	April 4, 2026	January 3, 2026
Deferred contract liabilities included in:
Other current liabilities	$32,139	$35,690
Other non-current liabilities	35,725	40,961
	$67,864	$76,651

Deferred revenue and costs related to SleepIQ® technology are currently recognized on a straight-line basis over the

product's estimated life of 4.5 years because the Company’s inputs are generally expended evenly throughout the

performance period. During the three months ended April 4, 2026 and March 29, 2025, the Company recognized revenue

of $11 million and $10 million, respectively, that was included in the deferred contract liability balances at the beginning of

the respective periods.

Revenue from goods and services transferred to customers at a point in time accounted for approximately 97% of

revenues for both the three months ended April 4, 2026 and March 29, 2025.

Net sales were as follows (in thousands):


	Three Months Ended
	April 4, 2026	March 29, 2025
Retail stores	$277,637	$344,442
Online, phone, chat and other	41,350	48,819
Total Company	$318,987	$393,261

Obligation for Sales Returns

The activity in the sales returns liability account was as follows (in thousands):


	Three Months Ended
	April 4, 2026	March 29, 2025
Balance at beginning of year	$12,817	$19,092
Additions that reduce net sales	11,496	18,787
Deductions from reserves	(12,047)	(21,102)
Balance at end of period	$12,266	$16,777


11 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

9. Stock-Based Compensation Expense

Total stock-based compensation expense was as follows (in thousands):


	Three Months Ended
	April 4, 2026	March 29, 2025
Stock awards(1)	$2,646	$2,933
Stock options	180	1,018
Total stock-based compensation expense (1)	$2,826	$3,951

(1) Changes in stock-based compensation expense include the cumulative impact of the change in the expected achievements of certain performance

targets.

10. Profit Sharing and 401(k) Plan

Under the Company’s profit sharing and 401(k) plan, eligible employees may defer up to 50% of their compensation on a

pre-tax basis, subject to Internal Revenue Service limitations. Each pay period, the Company makes a contribution equal

to a percentage of the employee’s contribution. Effective October 10, 2025, the Company suspended the 401(k) matching

contribution due to current business performance. During the three months ended March 29, 2025, the Company’s

contributions, net of forfeitures, $1.8 million.

11. Net Loss per Common Share

The components of basic and diluted net loss per share were as follows (in thousands, except per share amounts):


	Three Months Ended
	April 4, 2026	March 29, 2025
Net loss	$(50,297)	$(8,646)
Reconciliation of weighted-average shares outstanding:
Basic weighted-average shares outstanding	22,991	22,706
Dilutive effect of stock-based awards	—	—
Diluted weighted-average shares outstanding	22,991	22,706
Net loss per share – basic and diluted	$(2.19)	$(0.38)

For the three month periods ended April 4, 2026 and March 29, 2025, otherwise dilutive stock-based awards have been

excluded from the calculation of diluted weighted-average shares outstanding, as their inclusion would have had an anti-

dilutive effect on our net loss per diluted share. Additional potential dilutive stock-based awards totaling 3.1 million and

1.9 million for the three months ended April 4, 2026 and March 29, 2025, respectively, have been excluded from the

diluted net loss per share calculations because these stock-based awards were anti-dilutive.

12. Restructuring Costs

In the fourth quarter of 2023, the Company initiated cost reduction actions to reduce operating expenses and accelerate

gross margin initiatives, and recognized $84.5 million of restructuring costs through January 3, 2026. The Company has

incurred an additional $21.7 million and of restructuring costs during the three months ended April 4, 2026. Charges

incurred related to this initiative were comprised of contract termination costs, severance and employee-related benefits,

professional fees and other, and asset impairment charges and are included in restructuring costs in the Company’s

condensed consolidated statement of operations. The Company expects approximately $2 million of additional

restructuring costs to be incurred through the remainder of 2026, primarily due to severance and employee-related

benefits, contract termination costs, and asset impairment charges.


12 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

The following table provides a summary of the Company’s restructuring costs during the three months ended April 4, 2026

and March 29, 2025 (in thousands):


	Three Months Ended
	April 4, 2026	March 29, 2025
Cash restructuring costs:
Contract termination costs(1)	$1,551	$(114)
Severance and employee-related benefits	1,134	157
Professional fees and other	1,512	17
Total cash restructuring costs	4,197	60
Non-cash restructuring costs:
Asset impairments(2)	17,539	—
Total restructuring costs	$21,736	$60

(1) Primarily comprised of lease termination costs. Costs incurred during the three months ended March 29, 2025 were favorable to original estimates.

(2) Primarily comprised of impairments of lease right-of-use assets and property and equipment.

The following table provides the activity in the Company’s restructuring related liabilities, which are included within

accounts payable, compensation and benefits and other current liabilities on the condensed consolidated balance sheet

(in thousands):


	April 4, 2026	January 3, 2026
Balance at the beginning of year	$6,076	$3,341
Expenses	4,197	19,754
Cash payments	(4,133)	(17,019)
Balance at the end of the period	$6,140	$6,076

Since the initiation of cost reduction actions in the fourth quarter of 2023, the Company has recognized a cumulative

$106.2 million of restructuring costs, as follows (in thousands):


		Cumulative
		April 4, 2026
Cash restructuring costs:
Contract termination costs(1)		$24,396
Severance and employee-related benefits		18,856
Professional fees and other		9,073
Total cash restructuring costs		52,325
Non-cash restructuring costs:
Asset impairments(2)		53,902
Total restructuring costs		$106,227

(1)Primarily comprised of strategic-development partner contract termination costs and lease termination costs.

(2) Primarily comprised of impairments of strategic-development partner long-lived assets, lease right-of-use assets and property and equipment.


13 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

13. Income Taxes

Income tax expense was $0.3 million for the three months ended April 4, 2026, compared with income tax benefit of

$0.6 million for the same period one year ago.

The Company evaluates its deferred income taxes quarterly to determine if valuation allowances are required. As part of

this evaluation, the Company assess whether valuation allowances should be established for any deferred tax assets that

are not considered more likely than not to be realized, using all available evidence, both positive and negative. This

assessment considers, among other matters, the nature, frequency, and severity of historical losses, forecasts of future

profitability, taxable income in available carryback periods and tax planning strategies. In making such judgments,

significant weight is given to evidence that can be objectively verified. On the basis of this evaluation, as of April 4, 2026, a

valuation allowance of $55 million has been recorded to recognize only a portion of the deferred tax asset that is more

likely than not to be realized. The Company continues to assess the need for the valuation allowance and will make

adjustments when appropriate.

14. Segments

The Company’s chief operating decision maker (CODM), who is the Chief Executive Officer, assesses company-wide

performance and allocates resources based on consolidated financial information. Consequently, the Company views the

entire organization as one reportable segment and the strategic purpose of all operating activities is to support that one

segment.

The CODM manages the Company’s business activities as a single operating and reportable segment at the consolidated

level. The CODM uses net loss, as reported on the Company’s consolidated statement of operations, in evaluating

performance of the Company in determining how to allocate resources of the Company as a whole, including investing in

the Company’s product development, sales and marketing campaigns, and employee compensation. The measure of

segment assets that is reviewed by the CODM is reported within the consolidated balance sheet as consolidated total

assets. The CODM also uses consolidated earnings or losses before interest, taxes, depreciation and amortization

(Adjusted EBITDA) as the basis for the CODM to evaluate the performance of the Company.

The following is a summary of the significant expense categories and consolidated net loss details provided to the CODM

(in thousands):


	Three Months Ended
	April 4, 2026	March 29, 2025
Net Sales	$318,987	$393,261

Less:
Cost of sales	(134,372)	(152,726)
Marketing expenses	(79,102)	(97,940)
Selling expenses	(81,693)	(91,163)
General and administrative	(33,592)	(38,619)
Research and development	(5,348)	(10,903)
Restructuring costs	(21,736)	(60)
Interest expense	(13,103)	(11,081)
Income tax (expense) benefit	(338)	585
Net loss	$(50,297)	$(8,646)


14 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

15. Commitments and Contingencies

Warranty Liabilities

The activity in the accrued warranty liabilities account was as follows (in thousands):


	Three Months Ended
	April 4, 2026	March 29, 2025
Balance at beginning of period	$5,656	$6,947
Additions charged to costs and expenses for current-year sales	2,522	3,131
Deductions from reserves	(2,541)	(3,162)
Changes in liability for pre-existing warranties during the current year, including expirations	86	(405)
Balance at end of period	$5,723	$6,511

Legal Proceedings

The Company is involved from time to time in various legal proceedings arising in the ordinary course of its business,

including primarily commercial, product liability, employment and intellectual property claims. In accordance with U.S.

GAAP, the Company records a liability in its consolidated financial statements with respect to any of these matters when it

is both probable that a liability has been incurred and the amount of the liability can be reasonably estimated. If a material

loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of

loss is disclosed. With respect to currently pending legal proceedings, the Company has not established an estimated

range of reasonably possible material losses either because it believes that it has valid defenses to claims asserted

against it, the proceeding has not advanced to a stage of discovery that would enable it to establish an estimate, or the

potential loss is not material. The Company currently does not expect the outcome of pending legal proceedings to have a

material effect on its consolidated results of operations, financial position or cash flows. Litigation, however, is inherently

unpredictable, and it is possible that the ultimate outcome of one or more claims asserted against the Company could

adversely impact its consolidated results of operations, financial position or cash flows. The Company expenses legal

costs as incurred.

Purported Class Action Complaint

On September 27, 2024, a purported customer served a putative class action complaint on behalf of themself and a

putative class of California consumers against Sleep Number in the United States District Court for the Eastern District of

California alleging that Sleep Number’s beds are perpetually on sale in violation of California law. The plaintiff seeks

injunctive relief, damages and attorney’s fees. Sleep Number moved to dismiss the amended complaint, which motion the

Magistrate recommended be granted by the Court without prejudice. The Magistrate’s recommendation is pending with

the Court.


15 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS

Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to provide a

reader of the Company’s condensed consolidated financial statements with a narrative from the perspective of

management on its financial condition, results of operations, liquidity and certain other factors that may affect the

Company’s future results. MD&A is presented in seven sections:

•Forward-Looking Statements and Risk Factors

•Business Overview

•Results of Operations

•Liquidity and Capital Resources

•Non-GAAP Data Reconciliations

•Critical Accounting Policies

Forward-looking Statements and Risk Factors

The discussion in this Quarterly Report on Form 10-Q contains certain forward-looking statements that relate to

future plans, events, financial results or performance. You can identify forward-looking statements by those that

are not historical in nature, particularly those that use terminology such as “may,” “will,” “should,” “could,”

“expect,” “anticipate,” “believe,” “estimate,” “plan,” “project,” “predict,” “intend,” “potential,” “continue” or the

negative of these or similar terms. These statements are subject to certain risks and uncertainties that could

cause actual results to differ materially from the Company’s historical experience and its present expectations or

projections. These risks and uncertainties include, among others:

•Changes in economic conditions and consumer sentiment and related impacts on discretionary consumer spending;

•Interest rates remain elevated, and may further increase and impact the cost of servicing the Company’s

indebtedness;

•Availability of attractive and cost-effective consumer credit options;

•Ability to achieve the improvements, growth, cost-savings, efficiencies and other benefits related to its turnaround

strategy to avoid adverse effects and the costs to implement its turnaround strategy;

•Ability to continue as a going concern;

•Access to additional capital and its access to such capital or alternative financing options may depend on factors

beyond the Company’s control or require the Company to accept unfavorable terms;

•Ability to manage the Company’s credit agreement, which contains financial covenants and other restrictions on our

actions;

•Effectiveness and efficiency of the Company’s marketing strategy and promotions;

•Ability to execute Sleep Number’s Total Retail distribution strategy;

•Ability to compete effectively;

•Ability to achieve and maintain high levels of product and service quality;

•Ability to improve and expand the product line, anticipate and respond to changing consumer trends, and execute new

product introductions;

•Ability to protect the Company’s technology, trademarks and brand, and the adequacy of its intellectual property

rights;

•Dependence on, and ability to maintain working relationships with key suppliers and third parties, including some that

are the only source of supply or services currently used by the Company;

•Fluctuations in commodity prices or third-party delivery or logistics costs and other inflationary pressures;

•Risks inherent in global-sourcing activities, including tariffs, foreign regulation, geo-political turmoil, war, pandemics,

labor challenges, foreign currency fluctuations, inflation, climate or other disasters and resulting supply shortages, and

production and delivery delays and disruptions;

•Operating with minimal levels of inventory, which may leave the Company vulnerable to supply shortages;


16 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

•Risks of disruption in the operation of any of the Company’s facilities and operations, including manufacturing,

assembly, distribution, logistics, field services, home delivery, headquarters, product development, retail or customer

service operations;

•Ability to effectively complete potential future acquisitions, business combinations or divestitures;

•Sleep Number’s ability, and the ability of its suppliers and vendors, to attract, retain and motivate qualified and

effective personnel;

•Ability to comply with existing and changing government regulations and laws;

•Ability to identify and withstand cyber threats that could compromise the security of the Company’s systems or those

of third parties upon which it relies and could result in a data breach or business disruption;

•Risks associated with advancements in, adoption of or the failure to effectively adopt, artificial intelligence and related

technologies;

•Adequacy of the Company’s and third-party information systems, and costs and disruptions related to upgrading or

maintaining these systems;

•Volatility of Sleep Number stock, its removal from various stock indices and the potential negative effects of

shareholder activism or of changes in coverage by securities analysts;

•Unfavorable tax treatment;

•Environmental, social and governance risks, including increasing scrutiny and evolving regulatory and stakeholder

expectations; and

•Ability to adapt to climate change and readiness for legal or regulatory responses thereto.

Additional information concerning these, and other risks and uncertainties is contained under the caption “Risk

Factors” in Part I, Item 1A. in the Company’s Annual Report on Form 10-K and in Part II. Item 1A. in subsequent

Quarterly Reports on Form 10-Q.

The Company has no obligation to publicly update or revise any of the forward-looking statements contained in this

Quarterly Report on Form 10-Q.

Business Overview

Sleep Number is the leader in personalized sleep wellness. Its mattresses are designed to evolve with each sleeper to

help them feel and perform their best. With adjustable firmness, pressure-relieving support and temperature balancing

comfort built into every mattress, Sleep Number beds adapt to customers’ changing needs, night after night, year after

year. Backed by over 40 years of innovation, over 1,000 patents and patents pending, and billions of hours of sleep data,

Sleep Number has helped more than 16 million people achieve their best sleep. The fully integrated model ensures quality,

durability, and care at every step—from design and craftsmanship to delivery and long-term support. 

Sleep Number products are awarded the industry's top recognitions, including ranked #1 in customer satisfaction for

mattresses purchased in-store and online, and #1 in comfort, by J.D. Power. In addition, the company is the Official Sleep +

Wellness Partner of the NFL, marking a relationship that leverages players, team partnerships, and league-wide initiatives

to amplify brand awareness and drive consumer engagement. Sleep Number’s life-changing, differentiated smart

mattresses combine physical and digital innovations, integrating unparalleled physical comfort with a highly advanced

sleep wellness platform. The smart beds offer the Company’s signature firmness adjustability, enabling each sleeper

adjustable comfort. Embedded digital sensors learn the sleep needs of each individual; “sense and do” technology uses

the sensed data to automatically adjust the smart mattress to keep the sleeper comfortable throughout the night.

Temperature balancing technology supports the ideal climate for each sleeper and solves a prevalent sleep challenge.

Additionally, smart mattresses are an exceptional value, with personalized sleep insights delivered daily, new features

regularly added to all smart mattresses through over-the-air updates and prices to meet most budgets. Sleep Number’s

mattresses provide unmatched features, benefits and comfort that can lead to improved sleep health and wellness for

both sleepers.

The Company’s advantaged business model is supported by its consumer innovation strategy: an individualized, digital

sleep wellness platform, a network of millions of highly engaged Smart Sleepers who are loyal brand advocates, a

vertically integrated operating model and a team member culture of individuality.

The Company’s 3,000 mission-driven team members are focused on driving value creation, including our exclusive direct-

to-consumer selling in 577 stores and online, which meets customers whenever and wherever they choose to provide an


17 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

exceptional experience and a lifelong relationship. Additionally, the Company partners with world-leading institutions to

bring the power of 40 billion hours of longitudinal sleep data to sleep science and research.

In November 2025, the Company introduced its turnaround strategy “Sleep Number Shifts,” a focused, company-wide

effort to reposition the brand, expand reach to new customer groups, and reignite growth. The aim is to drive value for

shareholders, customers and team members with efforts rooted in the consumer through all dimensions of the business.

It is centered on three key areas:

•Product: The Company is simplifying its offering with the goal of growing its customer base while building on the

demand from repeat customers

•Marketing: The Company is modernizing its efforts by expanding channels and reach with new creative to better

connect with today’s consumer and drive engagement with a focus on better ROI

•Distribution: The Company is focused on optimizing store footprint as well as exploring opportunities to expand

distribution into new channels, both physical and digital.

“Sleep Number Shifts” is being implemented as the Company continues to execute cost savings and operating

efficiencies, including real estate optimization and right-sizing the fixed cost base. While the Company is focused on

implementing the “Sleep Number Shifts” and executing cost savings and operating efficiencies, it faces liquidity

challenges.

Results of Operations

Quarterly and Year-to-Date Results

Quarterly and year-to-date operating results may fluctuate significantly as a result of a variety of factors, including

increases or decreases in sales, timing, amount and effectiveness of advertising expenditures, changes in sales return

rates or warranty experience, timing of investments in growth initiatives and infrastructure, timing of store openings/

closings and related expenses, changes in net sales resulting from changes in the Company’s store base, timing of new

product introductions and related expenses, timing of promotional offerings, competitive factors, changes in commodity

costs, disruptions in global supplies or third-party service providers, seasonality of retail and bedding industry sales,

consumer sentiment and general economic conditions. The extent to which these external factors will impact the

Company’s business and its consolidated financial results will depend on future developments, which are highly uncertain

and cannot be predicted. Therefore, the historical results of operations may not be indicative of the results that may be

achieved for any future period.

Highlights

Financial highlights for the three months ended April 4, 2026 were as follows:

•Net sales for the three months ended April 4, 2026 decreased 19% to $319 million, compared with $393 million for the

same period one year ago. Demand was impacted by ongoing industry demand pressure and lower store traffic.

•The net sales change resulted from a 16% comparable sales decrease in Total Retail. For additional details, see the

components of total net sales change on page 19.

•Average sales per store (sales for stores open at least one year, Total Retail, including online, phone and chat) on a

trailing twelve-month basis for the period ended April 4, 2026 totaled $2.2 million, compared with $2.5 million for the

same period one year ago.

•Operating loss for the three months ended April 4, 2026 was $37 million, compared with operating income of

$2 million for the same period one year ago. The $39 million decrease in operating income was driven by the lower

gross profit, partially offset by a $17 million reduction in operating expenses. The Company’s first quarter operating

loss rate was impacted by the deleveraging impact of the 19% decrease in net sales.

•Adjusted EBITDA for the three months ended April 4, 2026 was $6 million, compared to $22 million for the same

period one year ago. The decrease was primarily due to higher net loss when compared to the same period one year

ago, partially offset by an increase restructuring costs and other non-recurring items. For additional details, see Non-

GAAP Data Reconciliations section on page 24.

•Gross profit margin of 57.9% for the three months ended April 4, 2026 compared to 61.2% for the same period one

year ago. See the gross profit discussion on page 20 for additional details.


18 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

•The $17 million year-over-year reduction in the Company’s operating expenses was due to lower sales and marketing

expenses, general and administrative expenses, and research and development expenses, partially offset by higher

restructuring costs.

•Net loss for the three months ended April 4, 2026 was $50 million, compared with $9 million for the same period one

year ago. Net loss per diluted share was $2.19, compared with $0.38 for the same period one year ago.

•The Company’s adjusted return on invested capital (Adjusted ROIC) was negative 13.1% on a trailing twelve-month

basis for the period ended April 4, 2026, compared with 7.2% for the comparable period one year ago. For additional

details, see Non-GAAP Data Reconciliations section beginning on page 24.

•The Company used $8 million in cash from operating activities for the three months ended April 4, 2026, compared

with $3 million for the same period one year ago.

•Free cash flow used $13 million for the three months ended April 4, 2026, compared with $7 million used for the same

period one year ago. For additional details, see Non-GAAP Data Reconciliations section on page 24.

•As of April 4, 2026, the Company had $606 million of borrowings under its credit facility.

The following table sets forth the Company’s results of operations expressed as dollars and percentages of net sales.

Figures are in millions, except percentages and per share amounts. Amounts may not add due to rounding differences.


	Three Months Ended
	April 4, 2026		March 29, 2025
Net sales	$319.0	100.0%	$393.3	100.0%
Cost of sales	134.4	42.1%	152.7	38.8%
Gross profit	184.6	57.9%	240.5	61.2%
Operating expenses:
Sales and marketing	160.8	50.4%	189.1	48.1%
General and administrative	33.6	10.5%	38.6	9.8%
Research and development	5.3	1.7%	10.9	2.8%
Restructuring costs	21.7	6.8%	0.1	0.0%
Total operating expenses	221.5	69.4%	238.7	60.7%
Operating (loss) income	(36.9)	(11.6%)	1.9	0.5%
Interest expense, net	13.1	4.1%	11.1	2.8%
Loss before income taxes	(50.0)	(15.7%)	(9.2)	(2.3%)
Income tax expense (benefit)	0.3	0.1%	(0.6)	(0.1%)
Net loss	$(50.3)	(15.8%)	$(8.6)	(2.2%)

Net loss per share:
Basic and diluted	$(2.19)		$(0.38)

Weighted-average number of common shares:
Basic and diluted	23.0		22.7

The percentage of total net sales, by dollar volume, was as follows:


	Three Months Ended
	April 4, 2026	March 29, 2025
Retail stores	87.0%	87.6%
Online, phone, chat and other	13.0%	12.4%
Total Company	100.0%	100.0%


19 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

The components of total net sales change, including comparable net sales changes, were as follows:


	Three Months Ended
	April 4, 2026	March 29, 2025
Sales change rates:
Retail comparable-store sales (1)	(17%)	(15%)
Online, phone and chat	(15%)	(12%)
Total Retail comparable sales change (1)	(16%)	(15%)
Net opened/closed stores and other	(3%)	(1%)
Total Company	(19%)	(16%)

(1)Stores are included in the comparable-store calculations in the 13th full month of operations. Stores that have been remodeled or repositioned within

the same shopping center remain in the comparable-store base.

Other sales metrics were as follows:


	Three Months Ended
	April 4, 2026	March 29, 2025
Average sales per store (1) (in thousands)	$2,170	$2,495
Average sales per square foot (1)	$700	$807
Stores > $2 million in net sales (2)	31%	51%
Stores > $3 million in net sales (2)	6%	15%
Average revenue per mattress unit – Total Retail (3)	$6,021	$5,992

(1)Trailing-twelve months Total Retail comparable sales per store open at least one year.

(2)Trailing-twelve months for stores open at least one year (excludes Online, Phone and Chat sales).

(3)Represents Total Retail net sales divided by Total Retail mattress units.

The number of retail stores operating was as follows:


	Three Months Ended
	April 4, 2026	March 29, 2025
Beginning of period	600	640
Opened	—	2
Closed	(23)	(5)
End of period	577	637


20 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

Comparison of Three Months Ended April 4, 2026 with Three Months Ended March 29, 2025

Net sales

Net sales for the three months ended April 4, 2026 of $319 million decreased 19% from $393 million for the same period

one year ago driven by lower volume and reduced store count. Macro environment and weather conditions in January and

early February in the three months ended April 4, 2026 had a significant negative impact on net sales. The net sales

change consisted primarily of a 16% Total Retail comparable sales decrease.

The $74 million net sales decrease compared with the same period one year ago was comprised of the following: (i) a

$54 million decrease in Total Retail comparable net sales; (ii) a $7 million decrease from online, phone and chat; and (iii) a

$13 million decrease from net store closings and other. Total Retail mattress unit sales decreased 19% compared with the

prior year. Total Retail average revenue per mattress unit increased to $6,021, compared with $5,992 in the prior-year

period.

Gross profit

Gross profit of $185 million for the three months ended April 4, 2026 decreased by $56 million, or 23%, compared with

$241 million for the same period one year ago. The gross profit margin totaled 57.9% of net sales for the three months

ended April 4, 2026, compared to 61.2% in the prior-year comparable period.

The current-year gross profit margin decrease of 3.3 ppt was affected by the following items: (i) an unfavorable product

mix decreased the rate by 1.4 ppt; (ii) unfavorable cost variances and other non-mattress unit sales and warranty related

revenue deleveraged the rate by 1.4 ppt; and (iii) higher discounts on close-out models deleveraged the rate by 0.5 ppt.

Sales and marketing expenses

Sales and marketing expenses for the three months ended April 4, 2026 were $161 million, or 50.4% of net sales,

compared with $189 million, or 48.1% of net sales, for the same period one year ago. The current-year sales and

marketing expenses rate increase of 2.3 ppt. was primarily due to the deleveraging impact of an 19% net sales decline,

partially offset by a 15% decrease in sales and marketing expenses including a 32% lower media spend.

General and administrative expenses

General and administrative (G&A) expenses totaled $34 million, or 10.5% of net sales, for the three months ended April 4,

2026, compared with $39 million, or 9.8% of net sales, in the prior-year period. The changes in G&A expenses consisted

mainly of: (i) a $3 million decrease in employee compensation; (ii) a $2 million year-over-year decrease in company-wide,

performance-based incentive compensation; and (iii) a $1 million decrease in depreciation and amortization; offset by (iv)

a $1 million increase in professional and consulting fees. The G&A expenses rate increased by 0.7 ppt. in the current-year

period, compared with the same period one year ago due to the items discussed above offset by the deleveraging impact

of lower net sales.

Research and development expenses

Research and development (R&D) expenses totaled $5 million for the three months ended April 4, 2026, compared with

$11 million with the same period one year ago. While the Company’s consumer innovation pipeline remains robust, it is re-

prioritizing R&D resources in this highly constrained environment. Moving forward, the Company’s innovation agenda will

focus on maintaining and improving the Company’s core technologies and introducing additional advancements, while

driving costs out of the product.

Interest expense, net

Interest expense, net totaled $13 million for the three months ended April 4, 2026, compared to $11 million for the same

period one year ago. The increase was due to an increase in the average debt outstanding compared to the same period

one year ago offset slightly by a lower weighted-average interest rate.


21 \| 1Q 2026 FORM 10-Q		SLEEP NUMBER CORPORATION

Table of Contents

Restructuring Costs

Restructuring costs for the three months ended April 4, 2026 were $22 million, compared with $0.1 million for the same

period one year ago. Charges incurred related to this initiative were comprised of contract termination costs, severance

and employee-related benefits, professional fees and other, and asset impairment charges. These costs are included in

the restructuring costs line in the Company’s condensed consolidated statement of operations. The Company expects an

additional $2 million of restructuring costs to be incurred through the remainder of 2026, primarily due to severance and

employee-related benefits, contract termination costs, and asset impairment charges. See Note 12, Restructuring Costs,

of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1, Financial Information, of this

Quarterly Report on Form 10-Q for further information on restructuring costs.

Income tax expense (benefit)

Income tax expense was $0.3 million for the three months ended April 4, 2026, compared with a benefit of $0.6 million for

the same period one year ago. The change in income tax expense was primarily due to state tax expense and discrete

items recognized in the three months ended April 4, 2026, while federal tax losses did not create a benefit due to the

deferred tax valuation allowance.

The Company evaluates its deferred income taxes on a quarterly basis to determine if valuation allowances are required.

As part of this evaluation, the Company assess whether valuation allowances should be established for any deferred tax

assets that are not considered more likely than not to be realized, using all available evidence, both positive and negative.

This assessment considers, among other matters, the nature, frequency, and severity of historical losses, forecasts of

future profitability, taxable income in available carryback periods and tax planning strategies. In making such judgments,

significant weight is given to evidence that can be objectively verified. On the basis of this evaluation, as of April 4, 2026, a

valuation allowance of $55 million has been recorded to recognize only a portion of the deferred tax asset that is more

likely than not to be realized. The Company continues to assess the need for the valuation allowance and will make

adjustments when appropriate.

Liquidity and Capital Resources

Going Concern Considerations